Dr Robert Jackson

Consultant and Scientific Advisory Board member

Robert Jackson obtained his PhD in biochemical pharmacology from the Institute of Cancer Research (University of London) followed by postdoctoral positions at Yale University and Scripps Clinic.

Appointments in multinational pharmaceutical companies included Director, Chemotherapy Department, at Warner-Lambert/Parke-Davis Pharmaceutical Research (Ann Arbor, Michigan) and Group Director, Cancer Research, at DuPont (Wilmington, Delaware).

In 1991 he became Vice President, Research and Development, at Agouron Pharmaceuticals (La Jolla, California), and in 1997 Chief Operating Officer of Chiroscience Ltd, Cambridge UK. As project manager or R&D director, he supervised the development of several marketed drugs, including the anticancer agents pentostatin, trimetrexate and losoxantrone, the HIV protease inhibitor nelfinavir, and the local anaesthetic chirocaine.

He is author of two books and over 170 other publications, mainly dealing with anticancer and antiviral drugs, and with theoretical pharmacology. Post-retirement, his activities have included chairing the Discovery Committee of Cancer Research UK, and industry consulting.

Interested in speaking with a consultant?

We’ll arrange a brief consultation for you with a specialist in our team.

Set up Consultation